(IN BRIEF) SCHOTT Pharma’s AGM on February 4, 2025, revealed strong fiscal results for FY 2024, including exceeding revenue targets and a promotion to the MDAX. Shareholders approved all agenda items, including the appointment of Dr. Wolfram Carius to the … Read the full press release →
Posted in Business, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged Annual General Meeting, appointment, corporate growth, dividend payout, Dr. Wolfram Carius, GLP-1 drugs, green financing, homecare solutions, INNOVATION, KPMG, leadership, Management, MDAX, mRNA, pharma industry, profitability, revenue guidance, SCHOTT Pharma, shareholder approval, shareholder engagement, Supervisory Board